Q2 EPS Estimate for Foghorn Therapeutics Lowered by Analyst

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Investment analysts at B. Riley decreased their Q2 2025 earnings estimates for shares of Foghorn Therapeutics in a report issued on Wednesday, May 14th. B. Riley analyst K. Patel now forecasts that the company will earn ($0.36) per share for the quarter, down from their prior estimate of ($0.32). B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.55) per share. B. Riley also issued estimates for Foghorn Therapeutics’ Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.49) EPS, FY2026 earnings at ($1.44) EPS and FY2027 earnings at ($1.89) EPS.

Foghorn Therapeutics (NASDAQ:FHTX) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.30). The firm had revenue of $5.95 million during the quarter, compared to analyst estimates of $4.96 million.

Several other equities analysts have also recently weighed in on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price target on shares of Foghorn Therapeutics in a research note on Thursday, May 15th. Citizens Jmp began coverage on shares of Foghorn Therapeutics in a report on Wednesday, April 23rd. They issued a “mkt outperform” rating and a $9.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of Foghorn Therapeutics in a research report on Wednesday, April 30th. Finally, Citigroup began coverage on shares of Foghorn Therapeutics in a research report on Wednesday, April 23rd. They set an “outperform” rating for the company. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $12.13.

Foghorn Therapeutics Stock Down 5.0%

Shares of FHTX opened at $4.21 on Monday. The stock has a market capitalization of $234.67 million, a P/E ratio of -2.19 and a beta of 3.13. Foghorn Therapeutics has a twelve month low of $2.94 and a twelve month high of $10.25. The company has a 50 day moving average of $3.97 and a 200-day moving average of $5.11.

Institutional Investors Weigh In On Foghorn Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of FHTX. Barclays PLC raised its stake in Foghorn Therapeutics by 191.6% in the third quarter. Barclays PLC now owns 39,920 shares of the company’s stock valued at $371,000 after purchasing an additional 26,228 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Foghorn Therapeutics in the fourth quarter valued at about $56,000. Wingate Wealth Advisors Inc. acquired a new position in Foghorn Therapeutics in the fourth quarter valued at about $134,000. Rhumbline Advisers raised its stake in Foghorn Therapeutics by 9.1% in the fourth quarter. Rhumbline Advisers now owns 36,384 shares of the company’s stock valued at $172,000 after purchasing an additional 3,049 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in Foghorn Therapeutics in the fourth quarter valued at about $75,000. Institutional investors and hedge funds own 61.55% of the company’s stock.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.